The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

Wolfe Research initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating.Maximize Your Portfolio with Data Driven ...

Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for Mounjaro ...

Aeon Biopharma Inc’s profitability metrics reveal strong financial health. The company currently boasts a gross margin of -92.52%. The profit margin, also known as the revenue ratio or gross profit ...

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

Aardvark Therapeutics plans a $100M IPO for metabolic treatments, targeting rare Prader-Willi syndrome with a potential ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats ...

BioPharma Credit PLC (OTCPK:BOPCF) had declared $0.0114/share quarterly dividend. Payable Feb. 28; for shareholders of record ...

Zenas BioPharma, Inc.’s ZBIO share price has surged by 13.37%, which has investors questioning if this is right time to sell.

Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations as part of ...